Dr Robert Henry Dennis Ii, MD | |
5207 Janesdale Ct, Glenn Dale, MD 20769-2307 | |
(301) 352-3488 | |
(301) 352-3489 |
Full Name | Dr Robert Henry Dennis Ii |
---|---|
Gender | Male |
Speciality | Plastic Surgery |
Location | 5207 Janesdale Ct, Glenn Dale, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437339348 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | D0039575 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Robert Henry Dennis Ii, MD 5207 Janesdale Ct, Glenn Dale, MD 20769-2307 Ph: (301) 352-3488 | Dr Robert Henry Dennis Ii, MD 5207 Janesdale Ct, Glenn Dale, MD 20769-2307 Ph: (301) 352-3488 |
News Archive
Johnson & Johnson Pharmaceutical Research & Development, announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.
MediNaturaâ„¢ Incorporated, a Delaware Corporation headquartered in greater Philadelphia, today announced an agreement to purchase the Heel Group's USA operations, which is expected to be completed in late August 2014.
Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.
The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.
› Verified 2 days ago